Dr Sodergren explores the uses of medical cannabis, describing its applications. He also discusses the future of cannabinoid research in the short- and long-term.
List view / Grid view
Filter the results
A new slow-release formulation and delivery system for the oral contraceptive pill has shown success in pre-clinical trials and could be taken once a month.
Astellas has announced that it will be acquiring Audentes Therapeutics at a total cost of $3 billion.
The UK NICE has extended its approval for olaparib, updating its formulation from eight capsules twice a day to two tablets twice daily.
The US Food and Drug Administration has announced new guidance for drug applications that include results from adaptive clinical trials.
Stress testing or forced degradation is well recognized as a fundamental part of the drug development process, specifically related to purity through control of stability.
NICE has approved palbociclib through the Cancer Drugs Fund, meaning that women with advanced breast cancer who have already received hormone therapy will now be eligible for palbociclib on the NHS.
The three largest UK political parties have published their manifestos for the upcoming election which focus on various pharma initiatives including the NHS, R&D, drug prices and mental health.
The FDA has granted early-action approval to Exservan for the treatment of ALS, which can be administered safely and easily without water.
The EC has released a report that has found generics and biosimilars decrease wasteful spending and maintain health quality in the EU.
The content sessions at CPhI Worldwide have revealed the coming trends that the pharmaceutical industry will see next year.
The investigational broadly neutralising antibody, N6LS, is to be developed by ViiV Healthcare for the treatment and prevention of HIV-1.
US Speaker Pelosi’s new drug pricing plan could impact small biotech companies, reducing their innovation by 90 percent, says new research.